Abstract | AIM: METHODS: Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB2-II, bulky type (>4 cm in diameter) squamous cell carcinoma of the uterine cervix were enrolled. Irinotecan (60 mg/m2 ) was administered intravenously on days 1 and 8 and nedaplatin (80 mg/m2 ) was also administered on day 1 of every 21-day cycle. After two cycles of chemotherapy, a radical hysterectomy was performed. Until 6 weeks after the surgery, three to five cycles of the regimen were added as adjuvant chemotherapy. The primary endpoint was the 2-year relapse-free survival rate. The response rates and toxicities were evaluated as secondary endpoints. RESULTS: Thirty-two patients from seven institutions were enrolled in this study. The median age was 48 years (range 25-75 years). The average follow-up period was 37.8 months (15-71 months). Twenty-three patients completed the regimen as planned. The objective response rate (complete response + partial response) for the neoadjuvant chemotherapy regimen was 81.2%. The 2-year and 5-year relapse-free-survival rates were 87.5% and 78.8%, respectively. The incidence of grade 3/4 neutropenia was 6.3% and 34.4% during neoadjuvant and adjuvant treatment, respectively. All other toxicities were well tolerated. CONCLUSION: Our treatment showed efficacy and tolerability for patients with locally advanced, bulky stage IB2-IIB cervical cancer. This suggests that treatment has the potential to improve the prognosis compared to concurrent chemo- radiotherapy.
|
Authors | Taisuke Mori, Hiroshi Makino, Tomoharu Okubo, Yoichiro Fujiwara, Morio Sawada, Haruo Kuroboshi, Hiroshi Tsubamoto, Homare Murakoshi, Takashi Motohashi, Jo Kitawaki, Kimihiko Ito |
Journal | The journal of obstetrics and gynaecology research
(J Obstet Gynaecol Res)
Vol. 45
Issue 3
Pg. 671-678
(Mar 2019)
ISSN: 1447-0756 [Electronic] Australia |
PMID | 30575239
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Copyright | © 2018 Japan Society of Obstetrics and Gynecology. |
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- Topoisomerase I Inhibitors
- Irinotecan
- nedaplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, surgery, therapy)
- Chemotherapy, Adjuvant
- Female
- Humans
- Hysterectomy
- Irinotecan
(therapeutic use)
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Organoplatinum Compounds
(therapeutic use)
- Prognosis
- Topoisomerase I Inhibitors
(therapeutic use)
- Treatment Outcome
- Uterine Cervical Neoplasms
(drug therapy, surgery, therapy)
|